The expression level of PD-L1 on circulating tumor cells (CTCs) has been applied to the immunotherapy for patients with non small cell lung cancer (6, 7), however CTC enrichment and the immune detection of PD-L1+ CTC remain challenges in routine clinical practices. Here, CD274 is linked to non-small cell lung carcinoma.